SOUTH SAN FRANCISCO, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology”; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced that ALX Oncology leadership will participate in the Wells Fargo Executive Biotech Summit, TD Cowen 46th Annual Health Care Conference, and UBS Biotech Summit. The details of the meetings are as follows: Wells Fargo Executive Biotech Summit F ...

Core Insights - ALX Oncology Holdings Inc. plans to report its fourth quarter and full year 2025 financial results on February 27, 2026, before market open [1] - The company will host a teleconference to discuss the financial results [1] Financial Results Webcast Information - The webcast is scheduled for February 27, 2026, at 5:30 AM PT / 8:30 AM ET [2] - Access to the conference call can be obtained by dialing 1-877-407-0755 or +1-201-389-0913 [2] Company Overview - ALX Oncology is a clinical-stage biotechnology company focused on developing novel therapies for cancer treatment [4] - The lead candidate, evorpacept, is being evaluated in multiple clinical trials across various cancer indications [4] - The second candidate, ALX2004, is an EGFR-targeted antibody-drug conjugate currently in a Phase 1 trial for EGFR-expressing solid tumors [4]

Group 1 - Kiora Pharmaceuticals will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, at 3:20 p.m. ET, with a live webcast available on their investor relations website [1] - Kiora Pharmaceuticals is a clinical-stage biotechnology company focused on developing advanced therapies for retinal diseases, utilizing innovative small molecules to address vision loss [2] - The company is developing KIO-104 for retinal inflammation and KIO-301 for retinitis pigmentosa, choroideremia, and Stargardt disease, with the latter being a molecular photoswitch aimed at restoring vision [2] Group 2 - Kiora Pharmaceuticals encourages investors to follow their updates on social media platforms like X and LinkedIn, as well as to visit their website for relevant information [3]

Group 1: Walmart - Walmart shares fell over 2% in premarket trading after the company's fiscal year guidance was softer than expected, with adjusted earnings per share projected between $2.75 and $2.85, below Wall Street's forecast of $2.96 [2][5] - Despite the recent dip, Walmart's stock has increased by more than 21% over the past year and nearly 175% over the last five years, reaching a market cap of $1 trillion earlier this month [5] - The company is under new leadership with CEO John Furner, who took over earlier this month, and investors are closely watching Walmart's future performance [5] Group 2: Federal Reserve - Minutes from the Federal Reserve's January meeting indicated a consensus on holding interest rates steady, but there was significant division regarding future monetary policy directions [2][3] - Some Fed members suggested that interest rates could decrease if inflation trends downward, while others believe that easing may not be necessary until clear signs of disinflation are observed [3] Group 3: Airline Industry - United Airlines announced changes to its frequent flyer program, stating that customers flying basic economy without the airline's credit card will earn fewer miles, aligning with similar moves by American Airlines and Delta Air Lines [12][13] - Cardholders will benefit from earning more points and receiving frequent flyer discounts, marking significant adjustments to the airline's loyalty program in over a decade [14] Group 4: Pharmaceutical Industry - FDA Commissioner Marty Makary warned that the U.S. is lagging behind China in early-stage drug development and suggested streamlining the process for initiating trials on new treatments [6][7] - Moderna's shares rose approximately 6% after the FDA agreed to review its experimental mRNA flu shot, reversing a previous refusal of the application [8]

CDI‑988 is the first oral antiviral drug candidate being developed for prevention and treatment of norovirus infectionsCompany to present Phase 1 data and updates from ongoing Phase 1b study conducted at Emory University School of MedicineNo approved antiviral therapies or vaccines for norovirus infections demonstrate an immediate market need BOTHELL, Wash., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that initial progress of a norovirus c ...

Core Viewpoint - Intellia Therapeutics, Inc. is set to host a conference call on February 26, 2026, to discuss its fourth quarter and full-year 2025 financial results and business updates [1]. Group 1: Company Overview - Intellia Therapeutics is a leading clinical-stage gene editing company focused on CRISPR-based therapies aimed at revolutionizing medicine [3]. - The company aims to develop novel, first-in-class medicines that address significant unmet medical needs and advance treatment paradigms for patients [3]. - Intellia is expanding its CRISPR-based platform with novel editing and delivery technologies to harness the full potential of gene editing [3]. Group 2: Conference Call Details - The conference call will take place at 8 a.m. ET on February 26, 2026 [1]. - U.S. callers can join the teleconference by dialing 1-833-316-0545, while international callers should dial 1-412-317-5726 [2]. - A replay of the call will be available for approximately 90 days on the Events page of Intellia's website [2].

Core Insights - Kane Biotech Inc. has signed non-exclusive distribution and sales agreements for its revyve Antimicrobial Wound Gel product line with Patient Care Medical and Life Biologics, enhancing its market presence in the U.S. [1][2] Group 1: Distribution Agreements - The agreements with Patient Care Medical and Life Biologics will expand Kane Biotech's presence in targeted sales channels and geographic markets, with Life Biologics distributing nationally and Patient Care Medical focusing on Louisiana, Mississippi, and the Gulf Coast [2][3] - Initial shipments of the revyve product line are being prepared for the near term [2] Group 2: Company Strategy and Product Information - Expanding the U.S. distribution network is a key priority for Kane Biotech, supporting its near-term commercialization objectives [3] - Kane Biotech is focused on developing novel wound care treatments that disrupt biofilms, which contribute to antibiotic resistance in wounds, with its revyve product line addressing both biofilms and wound bacteria [3] - The revyve Antimicrobial Wound Gel and its variants are U.S. FDA 510(k) cleared and Health Canada approved, indicating regulatory compliance and market readiness [3]

Core Insights - Regeneron Pharmaceuticals has announced that the FDA has accepted the Biologics License Application for garetosmab, which could become the first treatment for adults with fibrodysplasia ossificans progressiva (FOP) [1][5] Group 1: Disease Overview - FOP is an ultra-rare genetic disorder characterized by abnormal bone formation that leads to significant disability, with approximately 900 diagnosed cases worldwide [2] - The median age of survival for individuals with FOP is around 56 years, and most patients are wheelchair-bound by the age of 30 [2] Group 2: Clinical Trial and Efficacy - The BLA for garetosmab is supported by data from the Phase 3 OPTIMA trial, which showed that both doses of garetosmab (3 mg/kg and 10 mg/kg) significantly reduced the number and volume of new heterotopic ossification (HO) lesions compared to placebo [3] - Specifically, the 3 mg/kg dose resulted in a 94% reduction in new lesions (1 lesion vs. 19 lesions; p=0.0274), while the 10 mg/kg dose showed a 90% reduction (2 lesions vs. 19 lesions; p=0.0260) [3] - A post-hoc analysis indicated both doses achieved over 99% reduction in mean total volume of new HO lesions compared to placebo [3] Group 3: Safety Profile - Among the 63 participants in the OPTIMA trial, serious treatment-emergent adverse events were reported in 1 patient on the 3 mg/kg dose, 2 patients on the 10 mg/kg dose, and 2 patients on placebo [4] - Common adverse reactions (≥30% incidence) included epistaxis, increased hair growth, abscess, and acne [4] Group 4: Regulatory Status - Garetosmab has received Priority Review status from the FDA, indicating its potential to significantly improve treatment for serious conditions [5] - The drug has also been granted Fast Track and Orphan Drug Designations by the FDA, as well as Orphan Designation in the European Union [5] Group 5: Future Developments - A Phase 3 trial of garetosmab in adolescents and children with FOP, named OPTIMA 2, is planned to begin later this year [10]

BETHESDA, Md., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that the Company’s management team will participate in a fireside chat and one-on-one meetings at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, being held Wednesday, February 25th through Thursday, February 26th. Fireside ...

Core Viewpoint - NovaBridge Biosciences has appointed Dr. Emmett T. Cunningham, Jr. as Vice Chairman of the Board, which is expected to enhance the company's strategic direction and shareholder value through his extensive biopharma experience [1][3][7]. Company Overview - NovaBridge is a global biotechnology platform focused on accelerating access to innovative medicines, combining business development expertise with agile clinical development to advance breakthrough assets [9]. - The company operates a unique hub-and-spoke business model aimed at bridging the gap between unmet patient needs and transformative care [3][7]. Leadership Appointment - Dr. Cunningham brings over 25 years of experience in biopharma, having held leadership roles in venture capital and major pharmaceutical companies, including Blackstone Group and Pfizer [2][5][6]. - His appointment is seen as a positive endorsement of NovaBridge's mission to create shareholder value by expediting the development of transformative medicines [7]. Research and Development Focus - Dr. Cunningham will also join the Research and Development Committee of the Board, which is established to expedite innovation and long-term growth [7]. - The company is currently developing several drug candidates, including givastomig and VIS-101, targeting various cancers and eye diseases [10][12]. Pipeline Highlights - Givastomig is a bispecific antibody being evaluated in a Phase 2 study for Claudin 18.2-positive gastric cancer, following positive results from a Phase 1b study [11]. - VIS-101 is in a Phase 2a study for wet age-related macular degeneration and diabetic macular edema, aiming to provide more durable treatment benefits [12].